The Lancet: Convalescent Plasma As A Potential Therapy For COVID-19

Convalescent Plasma As A Potential Therapy For COVID-19: Introduction- The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and extracorporeal membrane oxygenation for the critically ill patients, specific drugs for this disease are still being researched. In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged. However, randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19. Convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate of patients with SARS whose condition continued to deteriorate despite treatment with pulsed methylprednisolone. Moreover, several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma. In 2014, the use of convalescent plasma collected from patients who had recovered from Ebola virus disease was recommended by WHO as an empirical treatment during outbreaks. A protocol for the use of convalescent plasma in the treatment of Middle East respiratory syndrome coronavirus was established in 2015. To read complete article- https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30141-9/fulltext Source-The Lancet Authors- Long Chen,Jing Xiong, Lei Bao, Yuan Shi

15 Likes

LikeAnswersShare
उपयोगी जानकारी दी है धन्यवाद दिया जाता है
Thank you for latest update...
Informative post....
Quite informative
Good description
Informative.
Informative
Impressive
Good post

Cases that would interest you